Shanghai Henlius Biotech Doses First Patient in Phase I/III Study of HLX13 for Hepatocellular Carcinoma
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the completion of first patient dosing in a...
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the completion of first patient dosing in a...
China’s Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced that it has received...
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has...
Chinese CDMO leader Porton Pharma Solutions Ltd. has entered into a strategic partnership with domestic...
Chinese biotech InnoCare Pharma (HKG: 9969, SHA: 688428) has administered the first patient dose in...
Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO,...
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard...
Bristol-Myers Squibb (BMS; NYSE: BMY) announced last week that it has received marketing authorization from...
US-based Merck Sharp & Dohme Inc. (MSD; NYSE: MRK) announced positive results from the Phase...
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced the initiation of clinical trials for its...
The US Food and Drug Administration (FDA) announced this week an indication extension approval for...
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the Phase III...
Germany-based pharmaceutical major Boehringer Ingelheim has entered into a multi-year strategic collaboration with Tempus (NASDAQ:...
China-based Hainan Haiyao Co., Ltd. (SHE: 000566) has entered into a five-year strategic collaboration agreement...
China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has obtained market authorization from China’s...
China-based North China Pharmaceutical Group Corporation (SHA: 600812) announced that it has received clinical trial...
South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration...
Merck KGaA (ETR: MRK) released its Q1 2025 financial results, reporting a 2.5% year-on-year (YOY)...
China-based CanSino Biologics Inc. (HKG: 6185), a specialist in vaccine development, has announced that it...
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval...